Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDβ2mnull mice

Stem Cells

Volumn 24, Issue 7, 2006, Pages 1814-1821

  Pirson, Laurence ^a   Baron, Frédéric ^a   Meuris, Nathalie ^a   Giet, Olivier ^a   Castermans, Emilie ^a   Greimers, Roland ^a   Di Stefano, Ivano ^a   Gothot, André ^a   Beguin, Yves ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Allogeneic stem cell transplantation; Chronic myeloid leukemia; Imatinib

Indexed keywords

CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBRONECTIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG INHIBITION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IRRADIATION; MOUSE; NONHUMAN; ANIMAL; BLOOD CELL; CELL CULTURE; CELL CYCLE; CELL MOTION; DRUG SCREENING; FETUS BLOOD; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METABOLISM; MOUSE MUTANT; MYELOID LEUKEMIA; NONOBESE DIABETIC MOUSE; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; APOPTOSIS; BLOOD CELLS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FETAL BLOOD; FIBRONECTINS; GLYCOPROTEINS; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHA5BETA1; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MICE, INBRED NOD; MICE, SCID; PEPTIDES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, CXCR4; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749062024     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2005-0290     Document Type: Article

References (40)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
2. Kurzrock R, Kantarjian HM, Druker BJ et al. Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-830.
3. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
4. Heinrich MC, Griffith DJ, Druker BJ et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932.
5. Mauro MJ, O'Dwyer M, Heinrich MC et al. STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-334.
6. Yee NS, Paek I, Besmer P. Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: Basis for radiosensitivity of white spotting and steel mutant mice. J Exp Med 1994;179:1777-1787.
7. Ogawa M, Matsuzaki Y, Nishikawa S et al. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 1991;174:63-71.
8. + cells into the myeloid lineage. Blood 1992;80:1405-1412.
9. Miller CL, Rebel VI, Helgason CD et al. Impaired steel factor responsiveness differentially affects the detection and long-term maintenance of fetal liver hematopoietic stem cells in vivo. Blood 1997;89:1214-1223.
10. Levesque JP, Leavesley DI, Niutta S et al. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 1995;181:1805-1815.
11. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: Stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood 1998;91:100-110.
12. Patchen ML, Fischer R, Schmauder-Chock EA et al. Mast cell growth factor enhances multilineage hematopoietic recovery in vivo following radiation-induced aplasia. Exp Hematol 1994;22:31-39.
13. Neta R, Williams D, Selzer F et al. Inhibition of c-kit ligand/steel factor by antibodies reduces survival of lethally irradiated mice. Blood 1993;81:324-327.
14. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979;300:1068-1073.
15. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
16. Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia. 1997;11(suppl 4):S15-S17. Review.
17. Esperou H, Boiron JM, Cayuela JM et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003;31:909-918.
18. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-2425.
19. Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-445.
20. Wong R, Giralt SA, Martin T et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment of myeloid malignancies in patients older than 55 years of age. Blood 2003;102:3052-3059.
21. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune response. Blood 1999;94:3234-3241.
22. McSweeney PA, Niederwieser D, Shizuru J et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
23. Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021-2030.
24. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407-4412.
25. Baron F, Baker JE, Storb R et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254-2262.
26. Kerbauy FR, Storb R, Hegenbart U et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005;19:990-997.
27. Baron F, Maris MB, Storer BE et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005;11:272-279.
28. Baron F, Maris MB, Sandmaier BM et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993-2003.
29. Giet O, Van Bockstaele DR, Di S et al. Increased binding and defective migration across fibronectin of cycling hematopoietic progenitor cells. Blood 2002;99:2023-2031.
30. Huygen S, Giet O, Artisien V et al. Adhesion of synchronized human hematopoietic progenitor cells to fibronectin and vascular cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo culture. Blood 2002;100:2744-2752.
31. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14-S18.
32. Bartolovic K, Balabanov S, Hartmann U et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004;103:523-529.
33. Deininger MW, Goldman JM, Lydon N et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
34. Holtz MS, Slovak ML, Zhang F et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-3800.
35. Giet O, Huygen S, Beguin Y et al. Cell cycle activation of hematopoietic progenitor cells increases very late antigen-5-mediated adhesion to fibronectin. Exp Hematol 2001;29:515-524.
36. Foguenne J, Huygen S, Greimers R et al. Modulation of homing properties of primitive progenitor cells generated by ex vivo expansion. Haematologica 2005;90:445-451.
37. + cells. Br J Haematol 2002;119:500-509.
38. + hemopoietic progenitor cells. Exp Hematol 1999;27:579-586.
39. Hoepfl J, Miething C, Grundler R et al. Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia 2002;16:1584-1588.
40. Mohty M, Blaise D, Olive D et al. Imatinib: The narrow line between immune tolerance and activation. Trends Mol Med 2005;11:397-402.